Founded by former OpenAI staff members and funded by Amazon and Google, Anthropic has raised the stakes in the GPT wars. Anthropic's Claude Desktop app often outshines its ChatGPT rival in various ...

Laptops are practical because you can take them with you. However, laptops have a relatively small screen. If you work on a mobile computer, it quickly becomes annoying to constantly switch programs.

I review privacy tools like hardware security keys, password managers, private messaging apps, and ad-blocking software. I also report on online scams and offer advice to families and individuals ...

Over the last several years, Apple has dramatically improved how it handles lithium-ion battery charging in iPhones, iPads, Macs, and Apple Watches. Across multiple system releases, the company moved ...

You can tap the equity in your home with a home equity loan, home equity line of credit or cash-out refinance to help buy a second home or investment property. Lenders look at your income, credit ...

We examine how AI is changing the future of work — and how, in many ways, that future is already here. Every tech company you can think of is jumping on the generative AI bandwagon and touting new ...

Ozempic is a prescription drug that comes as a liquid solution. It’s given as a subcutaneous injection using prefilled pens. You’ll likely inject a dose once per week. Your doctor will start your ...

Neal J. Riley is a digital producer for CBS Boston. He has been with WBZ-TV since 2014. His work has appeared in The Boston Globe and The San Francisco Chronicle. Neal is a graduate of Boston ...

Bio change signals: Banerjee updated her social media bio to list her CM terms without calling herself 'former', reflecting her refusal to formally resign. Unity call rebuffed: Her appeal to non-BJP ...

Crypto transactions settle faster, sometimes in minutes, compared to days for banks. Setting up a crypto wallet is quicker and easier than traditional bank accounts. Cryptocurrencies can protect ...

Recently, a pharmaceutical company came to the antibody-discovery specialist, Abveris, with a serious problem. The pharmaceutical company had tried and failed to develop a monoclonal antibody for an ...